NRIX
Nurix Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$26.80Close
$2.7BMarket cap
$12.17 – $27.7952-week range
Mid-januaryNext report · estimated
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 94 · stronger than 94% of stocks over 12 months
- Near its high 4% below its 52-week high
Cautions
- Past its pivot 11.7% above its $23.99 pivot
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
4%
1wk
up 5.8%
price change
1mo
up 13.0%
price change
12-month return
up 110%
market up 11% ·
its own up 118%
F-score
—
— Not assessed
Altman Z
8.58
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
5.1×
price / book
Earnings yield
down 11.5%
EBIT / enterprise value
Cheaper than
17%
of the market · expensive
Revenue growth
up 54%
year on year
EPS growth
—
latest quarter
Sales growth
up 8426%
latest quarter · +8506 pts
ROE
down 50%
return on equity
Free cash margin
down 314%
-$263.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Revenue reaccelerating (-29% then +54%)
Trade setup
ATR%
4.5%
$1.20 a day · 2×ATR $24.40
RS
94 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.2×
vs 50-day average
Up/down volume
0.82
50 sessions
Implied move
—
no scheduled report
Contractions
2
21% → 11%
Pivot
$23.99
11.7% above
Volume dry-up
1.3×
10 vs 50 sessions
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 34.2% over the year, from 76m to 102m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Oct 13, 2026
Results reaction
Oct 13, 2026+8% vs market2 sessions after results
Financials
- Net -315%
- Free cash -314%
- Cash
- Long-term debt
| FY2020Nov 30, 2020 | FY2021Nov 30, 2021 | FY2022Nov 30, 2022 | FY2023Nov 30, 2023 | FY2024Nov 30, 2024 | FY2025Nov 30, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $17.8M | $29.8M | $38.6M | $77.0M | $54.5M | $84.0M |
| Operating income | -$65.0M | -$117.9M | -$183.9M | -$155.1M | -$213.0M | -$285.7M |
| Net income | -$43.2M | -$117.2M | -$180.4M | -$143.9M | -$193.6M | -$264.5M |
| Net margin | -243% | -394% | -467% | -187% | -355% | -315% |
| Earnings per share | — | -$2.73 | -$3.71 | -$2.65 | -$2.88 | -$3.05 |
| Free cash flow | -$4.6M | -$90.0M | -$172.1M | -$89.8M | -$181.9M | -$263.5M |
| Free cash margin | -26% | -303% | -445% | -117% | -333% | -314% |
| Cash | $119.4M | $80.5M | $64.5M | $54.6M | $110.0M | $247.0M |
| Shareholders' equity | $290.3M | $342.3M | $303.7M | $200.5M | $527.0M | $538.7M |
| Shares outstanding | 38.86m | 44.66m | 47.17m | 48.72m | 75.87m | 101.81m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 13, 2026 | Quarterly ↗ | Aug 31, 2026 | 43d |
| Jul 9, 2026 | Quarterly ↗ | May 31, 2026 | 39d |
| Apr 8, 2026 | Quarterly ↗ | Feb 28, 2026 | 39d |
| Jan 28, 2026 | Annual ↗ | Nov 30, 2025 | 59d |
| Oct 9, 2025 | Quarterly ↗ | Aug 31, 2025 | 39d |
| Jul 9, 2025 | Quarterly ↗ | May 31, 2025 | 39d |
| Apr 8, 2025 | Quarterly ↗ | Feb 28, 2025 | 39d |
| Jan 28, 2025 | Annual ↗ | Nov 30, 2024 | 59d |
| Oct 11, 2024 | Quarterly ↗ | Aug 31, 2024 | 41d |
| Jul 11, 2024 | Quarterly ↗ | May 31, 2024 | 41d |
| Apr 10, 2024 | Quarterly ↗ | Feb 29, 2024 | 41d |
| Feb 15, 2024 | Annual ↗ | Nov 30, 2023 | 77d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 13, 2026 | Results ↗ |
| Jul 9, 2026 | Results ↗ |
| Jun 11, 2026 | Regulation FD · Other events ↗ |
| Jun 8, 2026 | Material agreement · Regulation FD ↗ |
| May 15, 2026 | Shareholder vote ↗ |
| Apr 8, 2026 | Results ↗ |
| Mar 6, 2026 | Other events ↗ |
| Jan 28, 2026 | Results ↗ |
| Jan 12, 2026 | Regulation FD ↗ |
| Dec 9, 2025 | Regulation FD · Other events ↗ |
| Nov 10, 2025 | Director or officer change ↗ |
| Oct 22, 2025 | Regulation FD · Other events ↗ |